@prefix dcterms: .
@prefix ns1: .
@prefix this: .
@prefix sub: .
@prefix schema: .
@prefix np: .
@prefix rdf: .
@prefix nt: .
@prefix xsd: .
@prefix rdfs: .
@prefix orcid: .
@prefix bl: .
@prefix npx: .
sub:Head {
this: np:hasAssertion sub:assertion;
np:hasProvenance sub:provenance;
np:hasPublicationInfo sub:pubinfo;
a np:Nanopublication .
}
sub:assertion {
bl:category bl:Disease .
sub:association rdf:object ;
rdf:predicate bl:treats;
rdf:subject ;
a rdf:Statement;
rdfs:label "iclusig ponatinib is a kinase inhibitor indicated for the treatment of adult patients with chronic phase accelerated phase or blast phase chronic myeloid leukemia cml or ph all for whom no other tyrosine kinase inhibitor tki therapy is indicated treatment of adult patients with t315i positive cml chronic phase accelerated phase or blast phase or t315i positive philadelphia chromosome positive acute lymphoblastic leukemia ph all iclusig is a kinase inhibitor indicated for the treatment of adult patients with chronic phase accelerated phase or blast phase chronic myeloid leukemia cml or ph all for whom no other tyrosine kinase inhibitor tki therapy is indicated treatment of adult patients with t315i positive cml chronic phase accelerated phase or blast phase or t315i positive philadelphia chromosome positive acute lymphoblastic leukemia ph all 1 limitations of use iclusig is not indicated and is not recommended for the treatment of patients with newly diagnosed chronic phase cml 5 7 limitations of use iclusig is not indicated and is not recommended for the treatment of patients with newly diagnosed chronic phase cml see warnings and precautions 5 7";
bl:association_type bl:ChemicalToDiseaseOrPhenotypicFeatureAssociation;
bl:provided_by ;
bl:relation schema:TreatmentIndication .
bl:category bl:Drug .
}
sub:provenance {
sub:assertion ns1:wasAttributedTo orcid:0000-0002-1468-3557 .
}
sub:pubinfo {
sub:sig npx:hasAlgorithm "RSA";
npx:hasPublicKey "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB";
npx:hasSignature "gbjZSswwLDxFeq8RkbUz7+V/FmsEPK6IcPPDcHfqYV5DtsO6O8lnIvBBX/wgd32VByPr92bBWEmyPLJjdCzvrmMSN9cExKDd/MfD0MVR22eAf6woFzwZ0hQE2SN8QlaDFmL0+/CRBpNuNHweQt5kIaF9u2nW4O5/VbRJktU/ro0=";
npx:hasSignatureTarget this: .
this: dcterms:created "2021-07-03T14:30:54.514+02:00"^^xsd:dateTime;
dcterms:creator orcid:0000-0002-1468-3557;
nt:wasCreatedFromProvenanceTemplate ;
nt:wasCreatedFromPubinfoTemplate ;
nt:wasCreatedFromTemplate .
}